Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.

Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.

PURPOSE: We previously reported that a panel of four kallikrein forms in blood-total, free, and intact prostate-specific antigen (PSA) and kallikrein-related peptidase 2 (hK2)-can reduce unnecessary biopsy in previously unscreened men with elevated total PSA. We aimed to replicate our findings in a...

Bibliográfalaš dieđut
Váldodahkkit:	Vickers, A, Cronin, A, Roobol, M, Savage, C, Peltola, M, Pettersson, K, Scardino, P, Schröder, F, Lilja, H
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	2010

Geahča maid

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands.
Dahkki: Gupta, A, et al.
Almmustuhtton: (2010)

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
Dahkki: Vickers, A, et al.
Almmustuhtton: (2010)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden.
Dahkki: Vickers, A, et al.
Almmustuhtton: (2008)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
Dahkki: Scardino Peter T, et al.
Almmustuhtton: (2008-07-01)

A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France.
Dahkki: Benchikh, A, et al.
Almmustuhtton: (2010)

A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France
Dahkki: Villers Arnauld, et al.
Almmustuhtton: (2010-11-01)

A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.
Dahkki: Vickers, A, et al.
Almmustuhtton: (2011)

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.
Dahkki: Vickers, A, et al.
Almmustuhtton: (2010)

Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.
Dahkki: Wenske, S, et al.
Almmustuhtton: (2009)

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
Dahkki: Steuber, T, et al.
Almmustuhtton: (2007)

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
Dahkki: Vickers, A, et al.
Almmustuhtton: (2009)

Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
Dahkki: Christensson, A, et al.
Almmustuhtton: (2011)

Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.
Dahkki: Klein, R, et al.
Almmustuhtton: (2010)

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
Dahkki: Vickers, A, et al.
Almmustuhtton: (2010)

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.
Dahkki: Savage, C, et al.
Almmustuhtton: (2010)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
Dahkki: Becker, C, et al.
Almmustuhtton: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
Dahkki: Becker, C, et al.
Almmustuhtton: (2003)

Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments.
Dahkki: Väisänen, V, et al.
Almmustuhtton: (2006)

Prostate kallikrein markers in diagnosis, risk stratification and prognosis.
Dahkki: Ulmert, D, et al.
Almmustuhtton: (2009)

Erratum: Evaluation of molecular forms of PSA and human kallikrein 2 in predicting biochemical failure following radical prostatectomy (International Journal of Cancer (2009) 125 (659-663) DOI:10.1002/ijc.23983)
Dahkki: Wenske, S, et al.
Almmustuhtton: (2010)

Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections.
Dahkki: Siivola, P, et al.
Almmustuhtton: (2000)

The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.
Dahkki: Haese, A, et al.
Almmustuhtton: (2003)

Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients.
Dahkki: Ylikoski, A, et al.
Almmustuhtton: (2001)

Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
Dahkki: Steuber, T, et al.
Almmustuhtton: (2006)

Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.
Dahkki: Carlsson, S, et al.
Almmustuhtton: (2012)

Five genetic variants associated with prostate cancer.
Dahkki: Vickers, A, et al.
Almmustuhtton: (2008)

Screening for prostate cancer: early detection or overdetection?
Dahkki: Vickers, A, et al.
Almmustuhtton: (2012)

Sensitive and specific immunodetection of human glandular kallikrein 2 in serum.
Dahkki: Becker, C, et al.
Almmustuhtton: (2000)

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
Dahkki: Vickers, A, et al.
Almmustuhtton: (2010)

Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
Dahkki: Steuber, T, et al.
Almmustuhtton: (2005)

An optimized prostate biopsy strategy in patients with a unilateral lesion on prostate magnetic resonance imaging avoids unnecessary biopsies
Dahkki: Auke Jager, et al.
Almmustuhtton: (2022-07-01)

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
Dahkki: Lilja, H, et al.
Almmustuhtton: (2007)

Re: Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study
Dahkki: Tayyar Alp Özkan
Almmustuhtton: (2015-12-01)

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Dahkki: Becker, C, et al.
Almmustuhtton: (2000)

Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
Dahkki: Ankerst, D, et al.
Almmustuhtton: (2014)

Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease.
Dahkki: Ylikoski, A, et al.
Almmustuhtton: (2002)

Taxon-specific evolution of glandular kallikrein genes and identification of a progenitor of prostate-specific antigen.
Dahkki: Olsson, A, et al.
Almmustuhtton: (2004)

Development of sensitive immunoassays for free and total human glandular kallikrein 2.
Dahkki: Väisänen, V, et al.
Almmustuhtton: (2004)

Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
Dahkki: Becker, C, et al.
Almmustuhtton: (2000)

Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
Dahkki: Steuber, T, et al.
Almmustuhtton: (2007)